References
- Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015 Apr;66:8–16. 2017-11-22.
- Sandstrom MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. Br J Dermatol. 2004 Jan;150(1):103–110.
- Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015 Jul;70(7):836–845.
- Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019 Aug;21(4):239–260.
- Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018 May;10(3):207–215.
- Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017 Jul;278(1):116–130.
- Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014 Oct;134(4):769–779.
- Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017 Jul;35(3):317–326.
- David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
- National Eczema Association. Atopic dermatitis in children 2020. [2020 Jun 17] Available from: https://nationaleczema.org/eczema/children/atopic-dermatitis/
- Sibbald C, Drucker AM. Patient burden of atopic dermatitis. Dermatol Clin. 2017 Jul;35(3):303–316.
- Ricci G, Bellini F, Dondi A, et al. Atopic dermatitis in adolescence. Dermatol Reports. 2012 Jan 2;4(1):e1.
- Dimitriades VR, Wisner E. Treating pediatric atopic dermatitis: current perspectives. Pediatric Health Med Ther. 2015;6:93–99.
- Taddeo D, Egedy M, Frappier J-Y. Adherence to treatment in adolescents. Paediatrics & Child Health. 2008;13(1):19–24.
- Drucker AM, Eyerich K, de Bruin-weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018 Mar;178(3):768–775.
- Edukulla R, Singh B, Jegga AG, et al. Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression. J Biol Chem. 2015 May 22;290(21):13510–13520.
- Miake S, Tsuji G, Takemura M, et al. IL-4 augments IL-31/IL-31 receptor alpha interaction leading to enhanced Ccl 17 and Ccl 22 production in dendritic cells: implications for atopic dermatitis. Int J Mol Sci. 2019 Aug 20;20(16).
- Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014 May;14(5):433.
- Hönzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the cornified envelope, tight junction proteins, and ß-defensins in filaggrin-deficient skin equivalents. J Invest Dermatol. 2016 Mar;136(3):631–639.
- Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007 Jul;120(1):150–155.
- Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008 Mar;126(3):332–337.
- Kagami S, Saeki H, Komine M, et al. Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Clin Exp Immunol. 2005 Sep;141(3):459–466.
- Li R, Hadi S, Guttman-Yassky E. Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opin Biol Ther. 2019 Apr;19(4):367–380.
- Travers JB. Toxic interaction between Th2 cytokines and Staphylococcus aureus in atopic dermatitis. J Invest Dermatol. 2014 Aug;134(8):2069–2071.
- Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003 Sep 15;171(6):3262–3269.
- Regeneron Pharmaceuticals, Inc. Dupixent (dupilumab). [package insert]. U.S. Food and Drug Administration. Revised March 2019. [cited 2020 Jun 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s012lbl.pdf
- National Library of Medicine. Efficacy and safety of dupilumab in participants ≥12 to <18 years of age, with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03054428
- Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2019 Nov 6;156(1):44–56.
- Paller AS, Siegfried EC, Thaci D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020 Jun 20;83(5):1282–1293.
- Study to investigate the efficacy and safety of dupilumab administered with topical corticosteroids (TCS) in participants ≥6 to <12 years with severe Atopic Dermatitis (AD). Available from: https://ClinicalTrials.gov/show/NCT03345914
- National Library of Medicine. Safety, pharmacokinetics and efficacy of dupilumab in patients ≥6 months to <6 years with moderate-to-severe atopic dermatitis. Liberty AD PRESCHOOL. [2020 Jun 15] Available from: https://ClinicalTrials.gov/show/NCT03346434
- National Library of Medicine. Study to assess the long-term safety of dupilumab administered in participants ≥6 months to <18 years of age with Atopic Dermatitis (AD). [2020 Jun 17] Available from: https://ClinicalTrials.gov/show/NCT02612454
- National Library of Medicine. Dupilumab phase 4 study. Available from: https://ClinicalTrials.gov/show/NCT03411837
- National Library of Medicine. Study of patients receiving DUPIXENT® for Atopic Dermatitis (AD). Available from: https://ClinicalTrials.gov/show/NCT03428646
- National Library of Medicine. BioDay registry: data collection regarding the use of new systemic treatment options in patients with Atopic Dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03549416
- A study to evaluate the efficacy and safety of dupilumab in adult and adolescent patients with moderate-to-severe atopic hand and foot dermatitis. Available from: https://ClinicalTrials.gov/show/NCT04417894
- A study to determine the safety and tolerability of dupilumab (REGN668/SAR231893) in patients aged ≥6 to <18 years with atopic dermatitis (Eczema). Available from: https://ClinicalTrials.gov/show/NCT02407756
- Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017 Oct;48:68–73.
- Evaluation of the efficacy and safety of Lebrikizumab (LY3650150) in moderate to severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT04178967
- Evaluation of the efficacy and safety of Lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate1). Available from: https://ClinicalTrials.gov/show/NCT04146363
- Long-term safety and efficacy study of Lebrikizumab (LY3650150) in patients with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT04392154
- Study to assess the safety and efficacy of Lebrikizumab (LY3650150) in adolescent patients with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT04250350
- Safety and efficacy of Lebrikizumab (LY3650150) in combination with topical corticosteroid in moderate to severe atopic dermatitis. (ADhere). Available from: https://clinicaltrials.gov/ct2/show/NCT04250337
- Long-term extension trial in subjects with atopic dermatitis who participated in previous Tralokinumab Trials - ECZTEND. Available from: https://ClinicalTrials.gov/show/NCT03587805
- Tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis - ECZTRA. ECZema TRAlokinumab Trial no. 6. p. 6. Available from: https://ClinicalTrials.gov/show/NCT03526861
- Ferretti E, Corcione A, Pistoia V. The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. J Leukoc Biol. 2017 Sep;102(3):711–717.
- Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004 Jul;5(7):752–760.
- Cornelissen C, Lüscher-Firzlaff J, Baron JM, et al. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012 Jun-Jul;91(6–7):552–566.
- Ferretti E, Tripodo C, Pagnan G, et al. The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia. 2015 Apr;29(4):958–967.
- Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Oct;138(4):984–1010.
- Raap U, Gehring M, Kleiner S, et al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy. 2017 Apr;47(4):499–508.
- Kunsleben N, Rüdrich U, Gehring M, et al. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015 Jul;135(7):1908–1911.
- Bağci IS, Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018 Mar;141(3):858–866.
- Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015 Oct;26(5):545–558.
- Cornelissen C, Marquardt Y, Czaja K, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012 Feb;129(2):426–33, 433.e1-8.
- Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010 Jun;22(6):453–467.
- Fioranelli M, Roccia MG, Lotti T. Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis. Dermatol Ther. 2017 Jul;30(4).
- National Library of Medicine. A pharmacokinetics and safety study of nemolizumab in adolescent subjects with Atopic Dermatitis (AD). Available from: https://ClinicalTrials.gov/show/NCT03921411
- National Library of Medicine. A study to assess immunization responses in adult and adolescent participants with moderate-to-severe atopic dermatitis treated with nemolizumab. Available from: https://ClinicalTrials.gov/show/NCT04365387
- National Library of Medicine. Efficacy & safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03989349
- National Library of Medicine. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03985943
- National Library of Medicine. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03989206
- Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol. 2008 Nov 15;181(10):7420–7427.
- Haugh IM, Preston AK, Kivelevitch DN, et al. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018;12:3879–3883.
- National Library of Medicine. A study to evaluate risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis. [2020 Jun 15] Available from: https://clinicaltrials.gov/ct2/show/study/NCT03706040?term=biologic&cond=Atopic+Dermatitis&age=0&draw=2&rank=15
- Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. 2019 Apr;12(2):83–93.